- Home
- UFI vs ANL Comparison
UFI vs ANL Comparison
Compare UFI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFI
- ANL
- Stock Information
- Founded
- UFI 1969
- ANL 2004
- Country
- UFI United States
- ANL Cayman Islands
- Employees
- UFI N/A
- ANL N/A
- Industry
- UFI Textiles
- ANL
- Sector
- UFI Consumer Discretionary
- ANL
- Exchange
- UFI Nasdaq
- ANL Nasdaq
- Market Cap
- UFI 91.3M
- ANL 73.8M
- IPO Year
- UFI N/A
- ANL 2023
- Fundamental
- Price
- UFI $4.87
- ANL $1.47
- Analyst Decision
- UFI
- ANL Buy
- Analyst Count
- UFI 0
- ANL 2
- Target Price
- UFI N/A
- ANL N/A
- AVG Volume (30 Days)
- UFI 38.8K
- ANL 14.8K
- Earning Date
- UFI 04-30-2025
- ANL 08-08-2025
- Dividend Yield
- UFI N/A
- ANL N/A
- EPS Growth
- UFI N/A
- ANL N/A
- EPS
- UFI N/A
- ANL N/A
- Revenue
- UFI $590,261,000.00
- ANL N/A
- Revenue This Year
- UFI $1.08
- ANL N/A
- Revenue Next Year
- UFI $9.96
- ANL N/A
- P/E Ratio
- UFI N/A
- ANL N/A
- Revenue Growth
- UFI 2.51
- ANL N/A
- 52 Week Low
- UFI $4.25
- ANL $1.10
- 52 Week High
- UFI $7.91
- ANL $4.10
- Technical
- Relative Strength Index (RSI)
- UFI 47.76
- ANL 37.32
- Support Level
- UFI $4.83
- ANL $1.56
- Resistance Level
- UFI $5.12
- ANL $1.74
- Average True Range (ATR)
- UFI 0.22
- ANL 0.15
- MACD
- UFI -0.01
- ANL -0.01
- Stochastic Oscillator
- UFI 27.59
- ANL 12.50
About UFI Unifi Inc. New
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.